ArticleCureus2025
Comparative Effectiveness of Lifestyle Versus Pharmacologic Therapy in Non-alcoholic Fatty Liver Disease (NAFLD): A 12-Month Multicenter Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is a growing global health concern linked to metabolic syndrome (MetS) and insulin resistance.
objectiveThe objective of the study is to compare the effectiveness of lifestyle interventions versus pharmacological therapy in the management of NAFLD across multiple healthcare centers using a real-world observational cohort design. METHODOLOGY: This multicentric observational cohort study was conducted from January 2023 to December 2024 at the Lady Reading Hospital (LRH), Peshawar, and Hayatabad Medical Complex (HMC), Peshawar. The 12-month follow-up was completed by 367 (90.84%) of the 404 patients who were recruited. Participants were split into two groups: one for pharmaceutical treatment (n = 179) and another for lifestyle intervention (n = 188). At baseline and after a year, clinical, biochemical, and radiological data were evaluated. Statistical Package for the Social Sciences (SPSS) version 26 (IBM Corp., Armonk, NY, US) was used for data analysis.
resultsThe lifestyle group showed significantly greater reductions in weight (-4.52 ± 2.10 kg vs. -1.65 ± 1.44 kg; p < 0.001), body mass index (BMI) (-1.43 ± 0.65 vs. -0.52 ± 0.48 kg/m²; p < 0.001), alanine aminotransferase (ALT) (-18.77 ± 10.84 vs. -15.23 ± 9.45 U/L; p = 0.004), and FibroScan (transient elastography) scores (-1.98 ± 0.84 vs. -1.47 ± 0.78 kPa; p < 0.001) compared to the pharmacological group. ALT reduction > 30% was observed in 112 (59.57%) lifestyle patients versus 89 (49.72%) pharmacological patients (p = 0.048), and BMI reduction ≥ 5% in 106 (56.38%) vs. 41 (22.91%), respectively (p < 0.001).
conclusionLifestyle intervention is more effective than pharmacological therapy in improving metabolic and liver-related outcomes in NAFLD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.